Literature DB >> 541676

The immune response of the mouse to lymphocytic choriomeningitis virus. I. Circulating antibodies.

B Kimmig, F Lehmann-Grube.   

Abstract

A search was made in LCM virus-immune mice for virus-specific antibodies. With the help of an L-cell plaque assay, neutralizing antibody was readily detected. There were no essential differences between mouse strains, but marked differences existed between virus strains. Whereas the inoculation of either large or small doses of WE strain virus led to the early production of considerable concentrations of neutralizing antibody, in the case of E-350 strain virus, high doses were required and a much longer time interval had to elapse before the threshold of detection was attained. In addition to neutralizing antibody, LCM virus-infected mice produced sensitizing antibody (detected by the enhancing effect of an anti-mouse Ig antiserum on the ability of a serum to reduce virus infectivity) and complement-fixing antibody. Previous failures to detect neutralizing antibody in LCM virus-immune mice might have been caused by properties of the chosen virus, but in many instances lack of a suitable assay host is a more likely explanation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 541676     DOI: 10.1099/0022-1317-45-3-703

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

Authors:  C Sedlik; M Saron; J Sarraseca; I Casal; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

4.  Characterization of a nonvirulent variant of lymphocytic choriomeningitis virus.

Authors:  P R Brayton; H F Maassab
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice.

Authors:  P Seiler; U Kalinke; T Rülicke; E M Bucher; C Böse; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.

Authors:  M F Saron; C Fayolle; P Sebo; D Ladant; A Ullmann; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Antiviral immune responses of lymphocytic choriomeningitis virus-infected mice lacking CD8+ T lymphocytes because of disruption of the beta 2-microglobulin gene.

Authors:  F Lehmann-Grube; J Löhler; O Utermöhlen; C Gegin
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Clearance of lymphocytic choriomeningitis virus in antibody- and B-cell-deprived mice.

Authors:  A Cerny; S Sutter; H Bazin; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses.

Authors:  C López-Macías; U Kalinke; M Cascalho; M Wabl; H Hengartner; R M Zinkernagel; A Lamarre
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.

Authors:  K J Maloy; C Burkhart; T M Junt; B Odermatt; A Oxenius; L Piali; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.